Physicians' Academy for Cardiovascular Education

Changing focus in diabetes: From glucose to CV risk management

10' education - Aug. 27, 2018 - ESC 2018 - Munich, Germany - Stephan Jacob, MD - Cardio Metabolic Institute, Villingen-Schwenningen, Germany

Prof. Jacob gives an overview of new antidiabetic interventions that showed a reduction in CV and total mortality in CV risk patients, which seems to be independent of improved glycemic control.

Video navigation menu

  • HbA1c and its associations 00:51
  • Is reducing HbA1c really successful? 02:16
  • Is there new hope with new agents? 04:49
  • Multifactorial effects of new antidiabetic treatments 06:37
  • Evolution of T2DM management 07:21

Educational information

This lecture was part of a CME accredited symposium: "Targeting SGLT2 in clinical cardiology: Exploring the benefits in CV Risk, Diabetes & Heart failure" during ESC 2018 in Munich, Germany.

Faculty

Prof Stephan Jacob, MD - endocrinologist/diabetologist, University of Tübingen and Cardio Metabolic Institute, Villingen-Schwenningen, Germany

Disclosures

This recording was developed under auspices of PACE-CME. Views expressed in the recording are those of the presenter and do not necessarily reflect the views of PACE-CME.

Funding

Funding for this educational program was provided by an unrestricted educational grant from Boehringer Ingelheim/Lilly.

View slides of prof. Jacob

The information and data provided in this program were updated and correct at the time of the program development, but may be subject to change.

Share this page with your colleagues and friends: